DAWES KAREN A 4
4 · REPLIGEN CORP · Filed Feb 28, 2024
Insider Transaction Report
Form 4
REPLIGEN CORPRGEN
DAWES KAREN A
Director
Transactions
- Sale
Common Stock
2024-02-27$193.35/sh−1,000$193,350→ 87,367 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-27+4,626→ 0 totalExercise: $42.07Exp: 2028-05-16→ Common Stock (4,626 underlying) - Exercise/Conversion
Common Stock
2024-02-27$42.07/sh+4,626$194,616→ 88,367 total
Footnotes (1)
- [F1]This option is fully vested and exercisable.